Abstract
Forskolin activates a variety of adenylate cyclase systems and acts synergistically with receptor-mediated agonists which stimulate cyclic AMP production. The mechanism(s) and site(s) of forskolin action remain unclear. In C6-2B rat astrocytoma cells, forskolin stimulated greater than a 100-fold increase in cellular cyclic AMP content with a half-maximally effective concentration (EC50) of greater than 50 microM. Incubation of C6-2B cells with forskolin plus (-)-isoproterenol resulted in an increase in (-)-isoproterenol efficacy and potency. The EC50 for the forskolin-induced increase in (-)-isoproterenol potency was 22 nM, greater than 3 orders of magnitude lower than the EC50 for direct forskolin-stimulated cyclic AMP accumulation. Forskolin had no effect on beta-receptor affinity for (-)-isoproterenol as measured by competition for (-)-[125I]iodopindolol binding sites. Forskolin also augmented the responses to prostaglandin E1 and cholera toxin. Inhibition of protein synthesis with cycloheximide markedly reduced forskolin-stimulated cyclic AMP accumulation with little or no effect on the responses to (-)-isoproterenol, prostaglandin E1, or cholera toxin. The ability of forskolin to act synergistically with these agents was unaffected by cycloheximide treatment. These observations are compatible with a two-site model of forskolin action in C6-2B cells: a low-affinity site which mediates the direct action of forskolin to increase cellular cyclic AMP accumulation and a high-affinity site which mediates the potentiative action of forskolin. The low-affinity forskolin site appears to reside on a protein which is closely associated with the catalytic adenylate cyclase moiety and has a relatively shorter half-life than other components of the cyclase system. The high-affinity site resides on a more stable component of the adenylate cyclase system. The synergistic action of forskolin may involve an enhancement of the interaction between the guanine nucleotide-binding regulatory component and the catalytic component of the adenylate cyclase complex.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|